Knoll Aktiengesellschaft

Basf Aktiengesellschaft

Warner-lambert Company

Chemische Fabrik Berg Gmbh

Heinz Einig

Bernd W M&uuml;ller

Harald Hach

Raymond Eason

Richard C Thompson

Marco Thyes

Michael Roreger

Peter Klein

Gerhard Fischer

Dieter Hix

Volker Buehler

Alfred Reidelshoefer

Peter Dresen

Evamarie Balz

Baerbel Stieren

Matthias Hollmann

A pharmaceutical mixture comprising a profen is described which has a profen content of over 85% and contains up to 1% of a nonionic surfactant having an HLB of &gE;9 and also a customary disintegrant and a lubricant and optionally a microcrystalline cellulose.

Pharmaceutical mixture comprising a profen

Medicaments in the form of soft gelatin capsules contain paroxetin anhydrate or pharmaceutically acceptable salts thereof together with lipophilic carriers, namely silicone oils.

Stable pharmaceutical dosage form for paroxetin anhydrate

Drugs comprising modification D of doxazosin mesylate are described. They are suitable for treating high blood pressure.

Medicaments containing doxazosin mesylate of crystalline modification D

A pharmaceutical mixture comprising a profen and one or more additional active compounds is described which has a total active compound content of over 85% and contains up to 1%, based on the content of the profen, of a nonionic surfactant having an HLB of &gE;9 and a customary disintegrant and a lubricant.

Pharmaceutical mixture comprising a combination of a profen and other active compounds

Solid oral administration forms from which the active ingredients can be isolated only with difficulty are described and comprise, besides conventional ingredients, as addition a mixture of pharmacologically suitable fats or gel formers with surfactants. Addition of the mixtures impedes extraction of the active ingredients out of the administration forms.

Impeding the extraction of active ingredients out of tablets

Medicament form for the delivery of collagenase to wounds and process

A mixture of an alginate and a polyacrylate in a ratio of from 15:1 to 1:2 is suitable for the preparation of depot drug forms.

Sustained release tablet of a mixture of alginates and polyacrylates

An alginate-based depot drug form for which the rate of release of the active substance in vitro can be adjusted very precisely is described.

Alginate-based verapamil-containing depot drug form

Growing community of inventors

Neustadt, Germany

Heinz Einig